ADVB
Advanced Biomed Inc. Common Stock
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$9.34
−0.69%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 2.8K | 10.7K | — | 11.9K | — |
| Gross Profit | (2.8K) | (10.7K) | — | (11.9K) | — |
| Operating Expenses | |||||
| R&D Expense | 492.8K | 28.3K | 880.2K | 45.0K | 1.6M |
| SG&A Expense | 573.1K | 55.1K | 1.3M | 43.1K | 624.8K |
| General & Admin Expense | 530.0K | — | 1.3M | — | 624.8K |
| Selling & Marketing Expense | 7.2K | — | — | — | — |
| Other Expenses | 27.3K | 1.00 | 399.6K | 365.2K | 130.1K |
| Total Operating Expenses | 1.1M | 83.4K | 2.5M | 88.1K | 2.4M |
| Cost and Expenses | 1.1M | 94.1K | 2.5M | 100.0K | 2.4M |
| Operating Income (EBIT) | (1.1M) | (94.1K) | (2.5M) | (100.0K) | (2.4M) |
| Non-Operating | |||||
| Interest Income | 1.1K | 776.16 | 53.5K | 21.4K | 243.00 |
| Interest Expense | 112.00 | — | — | — | — |
| Net Interest Income | 940.55 | 776.16 | 53.5K | 21.4K | 243.00 |
| Other Non-Op Income/Expense | 422.8K | (7.4K) | (240.7K) | (21.5K) | (1.7M) |
| Non-Operating Income (excl Interest) | (31.0K) | — | — | — | — |
| EBT (Pre-Tax Income) | (673.0K) | (101.5K) | (2.8M) | (121.5K) | (4.0M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (677.6K) | (101.5K) | (2.8M) | (121.5K) | (4.0M) |
| Earnings from Cont. Ops | (673.0K) | (101.5K) | (2.8M) | (121.5K) | (4.0M) |
| Earnings from Discont. Ops | (4.6K) | — | — | — | — |
| Bottom Line Net Income | (677.6K) | (101.5K) | (2.8M) | (121.5K) | (4.0M) |
| Per Share | |||||
| Basic EPS | ($0.21) | ($0.09) | ($0.08) | ($0.11) | ($0.13) |
| Diluted EPS | ($0.21) | ($0.09) | ($0.08) | ($0.11) | ($0.13) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 1.3M | 1.1M | 1.1M | 1.1M | 1.1M |
| Diluted Shares Outstanding | 1.3M | 1.1M | 1.1M | 1.1M | 1.1M |
| Profitability Metrics | |||||
| EBITDA | (1.0M) | (83.4K) | (2.1M) | (88.1K) | (2.2M) |
| D&A | 59.9K | 10.7K | 399.6K | 11.9K | 130.1K |
| EBIT | (1.1M) | (94.1K) | (2.5M) | (100.0K) | (2.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026